2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Journal of the American Society of Hypertension

Volumn 12, Issue 8, 2018, Pages 579.e1-579.e73

  Whelton, Paul K ^a   Carey, Robert M ^a   Aronow, Wilbert S ^a   Casey, Donald E ^a   Collins, Karen J ^a   Dennison Himmelfarb, Cheryl ^a   DePalma, Sondra M ^a   Gidding, Samuel ^a   Jamerson, Kenneth A ^a   Jones, Daniel W ^a   MacLaughlin, Eric J ^a   Muntner, Paul ^a   Ovbiagele, Bruce ^a   Smith, Sidney C ^a   Spencer, Crystal C ^a   Stafford, Randall S ^a   Taler, Sandra J ^a   Thomas, Randal J ^a   Williams, Kim A ^a   Williamson, Jeff D ^a   Wright, Jackson T ^a   more..

^a NONE

Author keywords

AHA Scientific Statements; ambulatory care; antihypertensive agents; behavior modification; blood pressure; chronic kidney disease; diabetes; hypertension; hypertension emergency; lifestyle measures; measurement; nonpharmacologic treatment; resistant hypertension; risk reduction; secondary hypertension; systems of care; treatment adherence; treatment outcomes

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; AORTIC DISEASE; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAUSALITY; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; COGNITIVE DEFECT; COLLABORATIVE CARE TEAM; COMBINATION DRUG THERAPY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROL STRATEGY; DEMENTIA; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG CHOICE; ELECTRONIC HEALTH RECORD; EMERGENCY; ETHNIC DIFFERENCE; EVIDENCE BASED PRACTICE; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH LITERACY; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIFESTYLE MODIFICATION; MASKED HYPERTENSION; MEASUREMENT ACCURACY; MEDICAL DOCUMENTATION; MEDICAL INFORMATICS; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; METABOLIC SYNDROME X; METHODOLOGY; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RISK; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RACE DIFFERENCE; REGISTER; RESISTANT HYPERTENSION; SECONDARY PREVENTION; SELF MONITORING; SEX DIFFERENCE; SOCIAL WELFARE; SOCIAL WORK; SURGERY; TELEHEALTH; TOTAL QUALITY MANAGEMENT; VALVULAR HEART DISEASE; VULNERABLE POPULATION; WHITE COAT HYPERTENSION;

EID: 85053344623     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2018.06.010     Document Type: Article

References (447)

1. Gibbons, G.H., Harold, J.G., Jessup, M., et al. The next steps in developing clinical practice guidelines for prevention. Circulation 128 (2013), 1716–1717.
2. Gibbons, G.H., Shurin, S.B., Mensah, G.A., et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. Circulation 128 (2013), 1713–1715.
3. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. 2011, The National Academies Press, Washington, DC.
4. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. 2011, The National Academies Press, Washington, DC.
5. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation 129 (2014), 2329–2345.
6. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association, 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed September 15, 2017.
7. Halperin, J.L., Levine, G.N., Al-Khatib, S.M., et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 133 (2016), 1426–1428.
8. Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127 (2013), 268–310.
9. Jacobs, A.K., Anderson, J.L., Halperin, J.L., The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130 (2014), 1208–1217.
10. Arnett, D.K., Goodman, R.A., Halperin, J.L., et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. Circulation 130 (2014), 1662–1667.
11. Whelton, P.K., Carey, R.M., Aronow, W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 71 (2018), e13–e115.
12. Gibbons, G.H., Harold, J.G., Jessup, M., et al. The next steps in developing clinical practice guidelines for prevention. Circulation 128 (2013), 1716–1717.
13. Gibbons, G.H., Shurin, S.B., Mensah, G.A., et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. Circulation 128 (2013), 1713–1715.
14. Society of Actuaries. Build and Blood Pressure Study, Vol 1, 1959, The University of Michigan, Ann Arbor, MI.
15. Dawber, T.R., The Framingham Study: The Epidemiology of Atherosclerotic Disease. 1980, Harvard University Press, Cambridge, MA.
16. Effects of treatment on morbidity and mortality in hypertension. I. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 202 (1967), 1028–1034.
17. Effects of treatment on morbidity and mortality in hypertension: II. results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213 (1970), 1143–1152.
18. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 237 (1977), 255–261.
19. Moser, M., Roccella, E.J., The treatment of hypertension: a remarkable success story. J Clin Hypertens (Greenwich) 15 (2013), 88–91.
20. Chobanian, A.V., Bakris, G.L., Black, H.R., et al., the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
21. Reboussin, D.M., Allen, N.B., Griswold, M.E., et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71 (2018), e116–e135.
22. Fihn, S.D., Gardin, J.M., Abrams, J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126 (2012), e354–e471.
23. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128 (2013), e240–e327.
24. Gerhard-Herman, M.D., Gornik, H.L., et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 (2017), e726–e779.
25. Funder, J.W., Carey, R.M., Mantero, F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101 (2016), 1889–1916.
26. Fihn, S.D., Blankenship, J.C., Alexander, K.P., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 130 (2014), 1749–1767.
27. Lenders, J.W., Duh, Q.Y., Eisenhofer, G., et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99 (2014), 1915–1942.
28. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130 (2014), e199–e267.
29. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 (2017), e1159–e1195.
30. Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(suppl 2) (2014), S49–S73.
31. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122 (2013), 1122–1131.
32. Yancy, C., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136 (2017), e137–e161.
33. Eckel, R.H., Jakicic, J.M., Ard, J.D., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(suppl 2) (2014), S76–S99.
34. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
35. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129:suppl 2 (2014), S102–S138.
36. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127 (2013), e362–e425.
37. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(suppl 2) (2014), S1–S45.
38. Regitz-Zagrosek, V., Blomstrom, L.C., Borghi, C., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32 (2011), 3147–3197.
39. Mosca, L., Benjamin, E.J., Berra, K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. Circulation 123 (2011), 1243–1262.
40. Smith, S.C. Jr., Benjamin, E.J., Bonow, R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124 (2011), 2458–2473.
41. Greenland, P., Alpert, J.S., Beller, G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122 (2010), e584–e636.
42. Hiratzka, L.F., Bakris, G.L., Beckman, J.A., et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121 (2010), e266–e369.
43. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114 (2004), 555–576.
44. Elijovich, F., Weinberger, M.H., Anderson, C.A.M., et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension 68 (2016), e7–e46.
45. Brush, J.E. Jr., Handberg, E.M., Biga, C., et al. 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol 65 (2015), 2118–2136.
46. Rosendorff, C., Lackland, D.T., Allison, M., et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation 131 (2015), e435–e470.
47. Flynn, J.T., Daniels, S.R., Hayman, L.L., et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension 63 (2014), 1116–1135.
48. Go, A.S., Bauman, M.A., Coleman King, S.M., et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 63 (2014), 878–885.
49. O'Brien, E., Parati, G., Stergiou, G., et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 31 (2013), 1731–1768.
50. Drozda, J. Jr., Messer, J.V., Spertus, J., et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. Circulation 124 (2011), 248–270.
51. Artinian, N.T., Fletcher, G.F., Mozaffarian, D., et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 122 (2010), 406–441.
52. Calhoun, D.A., Jones, D., Textor, S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51 (2008), 1403–1419.
53. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
54. Rapsomaniki, E., Timmis, A., George, J., et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383 (2014), 1899–1911.
55. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
56. Rapsomaniki, E., Timmis, A., George, J., et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383 (2014), 1899–1911.
57. Rutan, G.H., Kuller, L.H., Neaton, J.D., et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 77 (1988), 504–514.
58. Sesso, H.D., Stampfer, M.J., Rosner, B., et al. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension 36 (2000), 801–807.
59. Stamler, J., Stamler, R., Neaton, J.D., Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 153 (1993), 598–615.
60. Benetos, A., Thomas, F., Bean, K., et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 162 (2002), 577–581.
61. Lindenstrom, E., Boysen, G., Nyboe, J., Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study. Am J Epidemiol 142 (1995), 1279–1290.
62. Zhao, L., Song, Y., Dong, P., et al. Brachial pulse pressure and cardiovascular or all-cause mortality in the general population: a meta-analysis of prospective observational studies. J Clin Hypertens (Greenwich) 16 (2014), 678–685.
63. Mosley, W.J., Greenland, P., Garside, D.B., et al. Predictive utility of pulse pressure and other blood pressure measures for cardiovascular outcomes. Hypertension 49 (2007), 1256–1264.
64. Franklin, S.S., Lopez, V.A., Wong, N.D., et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation 119 (2009), 243–250.
65. Kodama, S., Horikawa, C., Fujihara, K., et al. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. Am J Cardiol 113 (2014), 1058–1065.
66. Lim, S.S., Vos, T., Flaxman, A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2224–2260.
67. Forouzanfar, M.H., Liu, P., Roth, G.A., et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 317 (2017), 165–182.
68. Danaei, G., Ding, E.L., Mozaffarian, D., et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med, 6, 2009, e1000058.
69. Ford, E.S., Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. Circulation 123 (2011), 1737–1744.
70. Cheng, S., Claggett, B., Correia, A.W., et al. Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. Circulation 130 (2014), 820–828.
71. Willey, J.Z., Moon, Y.P., Kahn, E., et al. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc, 3, 2014, e001106.
72. Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 66 Svii (2015), S1–S305.
73. Wilson, P.W., Kannel, W.B., Silbershatz, H., et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159 (1999), 1104–1109.
74. Berry, J.D., Dyer, A., Cai, X., et al. Lifetime risks of cardiovascular disease. N Engl J Med 366 (2012), 321–329.
75. McEvoy, R.D., Antic, N.A., Heeley, E., et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 375 (2016), 919–931.
76. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
77. Rapsomaniki, E., Timmis, A., George, J., et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 383 (2014), 1899–1911.
78. Ettehad, D., Emdin, C.A., Kiran, A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
79. Guo, X., Zhang, X., Guo, L., et al. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep 15 (2013), 703–716.
80. Guo, X., Zhang, X., Zheng, L., et al. Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoS ONE, 8, 2013, e61796.
81. Huang, Y., Cai, X., Li, Y., et al. Prehypertension and the risk of stroke: a meta-analysis. Neurology 82 (2014), 1153–1161.
82. Huang, Y., Cai, X., Liu, C., et al. Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta-analysis. J Am Heart Assoc, 4, 2015, e001519.
83. Huang, Y., Cai, X., Zhang, J., et al. Prehypertension and Incidence of ESRD: a systematic review and meta-analysis. Am J Kidney Dis 63 (2014), 76–83.
84. Huang, Y., Su, L., Cai, X., et al. Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J 167 (2014), 160–168.e1.
85. Huang, Y., Wang, S., Cai, X., et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med, 11, 2013, 177.
86. Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
87. Lee, M., Saver, J.L., Chang, B., et al. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. Neurology 77 (2011), 1330–1337.
88. Shen, L., Ma, H., Xiang, M.X., et al. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol 112 (2013), 266–271.
89. Sundstrom, J., Arima, H., Jackson, R., et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 162 (2015), 184–191.
90. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials. J Hypertens 32 (2014), 2296–2304.
91. Wang, S., Wu, H., Zhang, Q., et al. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies. Int J Cardiol 168 (2013), 4857–4860.
92. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2015), 435–443.
93. Cushman, W.C., Ford, C.E., Cutler, J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4 (2002), 393–404.
94. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 995–1003.
95. Wald, D.S., Law, M., Morris, J.K., et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122 (2009), 290–300.
96. Muntner, P., Woodward, M., Mann, D.M., et al. Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis. Hypertension 55 (2010), 1339–1345.
97. Parikh, N.I., Pencina, M.J., Wang, T.J., et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med 148 (2008), 102–110.
98. Carson, A.P., Howard, G., Burke, G.L., et al. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 57 (2011), 1101–1107.
99. Vasan, R.S., Beiser, A., Seshadri, S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 287 (2002), 1003–1010.
100. Shihab, H.M., Meoni, L.A., Chu, A.Y., et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation 126 (2012), 2983–2989.
101. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
102. Weir, M.R., In the clinic: hypertension. Ann Intern Med 161 (2014), ITC1–ITC15.
103. Liu, C., Griffiths, C., Murray, A., et al. Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement. Blood Press Monit 21 (2016), 178–183.
104. Kantola, I., Vesalainen, R., Kangassalo, K., et al. Bell or diaphragm in the measurement of blood pressure?. J Hypertens 23 (2005), 499–503.
105. Pickering, T.G., Hall, J.E., Appel, L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111 (2005), 697–716.
106. Uhlig, K., Balk, E.M., Patel, K., et al. Self-Measured Blood Pressure Monitoring: Comparative Effectiveness. 2012, Agency for Healthcare Research and Quality (US), Rockville, MD.
107. Margolis, K.L., Asche, S.E., Bergdall, A.R., et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA 310 (2013), 46–56.
108. McManus, R.J., Mant, J., Haque, M.S., et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA 312 (2014), 799–808.
109. Siu, A.L., Screening for high blood pressure in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med 163 (2015), 778–786.
110. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
111. Pickering, T.G., Miller, N.H., Ogedegbe, G., et al. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 52 (2008), 10–29.
112. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. 2011, Royal College of Physicians (UK), London, UK.
113. Pickering, T.G., James, G.D., Boddie, C., et al. How common is white coat hypertension?. JAMA 259 (1988), 225–228.
114. Piper, M.A., Evans, C.V., Burda, B.U., et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the US Preventive Services Task Force. Ann Intern Med 162 (2015), 192–204.
115. Ohkubo, T., Kikuya, M., Metoki, H., et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 46 (2005), 508–515.
116. Fagard, R.H., Cornelissen, V.A., Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 25 (2007), 2193–2198.
117. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. 2011, Royal College of Physicians (UK), London, UK.
118. Asayama, K., Thijs, L., Li, Y., et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension 64 (2014), 935–942.
119. Mancia, G., Bombelli, M., Brambilla, G., et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 62 (2013), 168–174.
120. Pierdomenico, S.D., Cuccurullo, F., Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am. J Hypertens 24 (2011), 52–58.
121. Viera, A.J., Hinderliter, A.L., Kshirsagar, A.V., et al. Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring. Am. J Hypertens 23 (2010), 1190–1197.
122. Viera, A.J., Lin, F.C., Tuttle, L.A., et al. Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit 19 (2014), 208–215.
123. Stergiou, G.S., Asayama, K., Thijs, L., et al. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension 63 (2014), 675–682.
124. Tomiyama, M., Horio, T., Yoshii, M., et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens 19 (2006), 880–886.
125. Levey, A.S., Bosch, J.P., Lewis, J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999), 461–470.
126. Calhoun, D.A., Jones, D., Textor, S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51 (2008), 1403–1419.
127. Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation 113 (2006), e463–e654.
128. Funder, J.W., Carey, R.M., Fardella, C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93 (2008), 3266–3281.
129. Funder, J.W., Carey, R.M., Mantero, F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101 (2016), 1889–1916.
130. Pedrosa, R.P., Drager, L.F., Gonzaga, C.C., et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 58 (2011), 811–817.
131. Kump, K., Whalen, C., Tishler, P.V., et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med 150 (1994), 735–741.
132. Johns, M.W., A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14 (1991), 540–545.
133. Grossman, E., Messerli, F.H., Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 125 (2012), 14–22.
134. Lenders, J.W., Duh, Q.Y., Eisenhofer, G., et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99 (2014), 1915–1942.
135. Nieman, L.K., Biller, B.M., Findling, J.W., et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 93 (2008), 1526–1540.
136. Lurbe, E., Cifkova, R., Cruickshank, J.K., et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27 (2009), 1719–1742.
137. Berglund, G., Andersson, O., Wilhelmsen, L., Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 2 (1976), 554–556.
138. Hassan-Smith, Z., Stewart, P.M., Inherited forms of mineralocorticoid hypertension. Curr Opin Endocrinol Diabetes Obes 18 (2011), 177–185.
139. Katznelson, L., Laws, E.R. Jr., Melmed, S., et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99 (2014), 3933–3951.
140. Goldstein, L.B., Bushnell, C.D., Adams, R.J., et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 (2011), 517–584.
141. Cortese, S., Holtmann, M., Banaschewski, T., et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol. Psychiatry 54 (2013), 227–246.
142. Wolraich, M., Brown, L., Brown, R.T., et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128 (2011), 1007–1022.
143. Newcomer, J.W., Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68:suppl 1 (2007), 20–27.
144. Willey, J.Z., Moon, Y.P., Kahn, E., et al. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc, 3, 2014, e001106.
145. Mesas, A.E., Leon-Munoz, L.M., Rodriguez-Artalejo, F., et al. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr 94 (2011), 1113–1126.
146. Liu, Y., Yang, M.-S., Yuan, J.-Y., Immunosuppressant utilization and cardiovascular complications among Chinese patients after kidney transplantation: a systematic review and analysis. Int Urol Nephrol 45 (2013), 885–892.
147. Penninga, L., Penninga, E.I., Moller, C.H., et al. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev, 5, 2013, CD008817.
148. Xue, W., Zhang, Q., Xu, Y., et al. Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. Chin Med J 127 (2014), 2376–2381.
149. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
150. Montori, V.M., Young, W.F. Jr., Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 31 (2002), 619–632 xi.
151. Cooper, C.J., Murphy, T.P., Cutlip, D.E., et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 (2014), 13–22.
152. Riaz, I.B., Husnain, M., Riaz, H., et al. Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol 114 (2014), 1116–1123.
153. Barbe, F., Duran-Cantolla, J., Capote, F., et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 181 (2010), 718–726.
154. Martinez-Garcia, M.A., Capote, F., Campos-Rodriguez, F., et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA 310 (2013), 2407–2415.
155. Lozano, L., Tovar, J.L., Sampol, G., et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. J Hypertens 28 (2010), 2161–2168.
156. Muxfeldt, E.S., Margallo, V., Costa, L.M., et al. Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial. Hypertension 65 (2015), 736–742.
157. Pedrosa, R.P., Drager, L.F., de Paula, L.K., et al. Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial. Chest 144 (2013), 1487–1494.
158. Neter, J.E., Stam, B.E., Kok, F.J., et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42 (2003), 878–884.
159. Whelton, P.K., Kumanyika, S.K., Cook, N.R., et al. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr 65 (1997), 652S–660S.
160. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 267 (1992), 1213–1220.
161. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 157 (1997), 657–667.
162. Sacks, F.M., Svetkey, L.P., Vollmer, W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344 (2001), 3–10.
163. Appel, L.J., Champagne, C.M., Harsha, D.W., et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 289 (2003), 2083–2093.
164. Appel, L.J., Moore, T.J., Obarzanek, E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336 (1997), 1117–1124.
165. Mozaffarian, D., Fahimi, S., Singh, G.M., et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 371 (2014), 624–634.
166. Aburto, N.J., Ziolkovska, A., Hooper, L., et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ, 346, 2013, f1326.
167. He, F.J., Li, J., MacGregor, G.A., Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ, 346, 2013, f1325.
168. Graudal, N.A., Hubeck-Graudal, T., Jurgens, G., Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 25 (2012), 1–15.
169. Whelton, P.K., Appel, L.J., Espeland, M.A., et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 279 (1998), 839–846.
170. Whelton, P.K., He, J., Cutler, J.A., et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 277 (1997), 1624–1632.
171. Geleijnse, J.M., Kok, F.J., Grobbee, D.E., Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 17 (2003), 471–480.
172. World Health Organization. Guideline: Potassium Intake for Adults and Children. 2012, World Health Organization, Geneva, Switzerland.
173. Whelton, P.K., He, J., Health effects of sodium and potassium in humans. Curr Opin Lipidol 25 (2014), 75–79.
174. Aburto, N.J., Hanson, S., Gutierrez, H., et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ, 346, 2013, f1378.
175. Cornelissen, V.A., Smart, N.A., Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc, 2, 2013, e004473.
176. Carlson, D.J., Dieberg, G., Hess, N.C., et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis. Mayo Clin Proc 89 (2014), 327–334.
177. Garcia-Hermoso, A., Saavedra, J.M., Escalante, Y., Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials. Obes Rev 14 (2013), 919–928.
178. Rossi, A.M., Moullec, G., Lavoie, K.L., et al. The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example. Can J Cardiol 29 (2013), 622–627.
179. Whelton, S.P., Chin, A., Xin, X., et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 136 (2002), 493–503.
180. Xin, X., He, J., Frontini, M.G., et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 38 (2001), 1112–1117.
181. Roerecke, M., Kaczorowski, J., Tobe, S.W., et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2 (2017), e108–e120.
182. Stewart, S.H., Latham, P.K., Miller, P.M., et al. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction 103 (2008), 1622–1628.
183. Dickinson, H.O., Mason, J.M., Nicolson, D.J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24 (2006), 215–233.
184. Wallace, P., Cutler, S., Haines, A., Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption. BMJ 297 (1988), 663–668.
185. Lang, T., Nicaud, V., Darne, B., et al. Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group. J Epidemiol Community Health 49 (1995), 610–616.
186. National Institute on Alcohol Abuse and Alcoholism (NIAAA). What Is A Standard Drink? Available at: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink. Accessed: August 16, 2017.
187. Inder, J.D., Carlson, D.J., Dieberg, G., et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertension Res 39 (2016), 88–94.
188. National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure With DASH–How Do I Make the DASH? Available at: https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to. Accessed September 18, 2017.
189. Top 10 DASH Diet Tips. Available at: http://dashdiet.org/dash_diet_tips.asp. Accessed September 18, 2017.
190. Lloyd-Jones, D.M., Evans, J.C., Levy, D., Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 294 (2005), 466–472.
191. Ozyilmaz, A., Bakker, S.J., de Zeeuw, D., et al. Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. Nephrol Dial Transplant 28 (2013), 2805–2815.
192. Peters, S.A., Huxley, R.R., Woodward, M., Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. Stroke 44 (2013), 2394–2401.
193. Schoenfeld, S.R., Kasturi, S., Costenbader, K.H., The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 43 (2013), 77–95.
194. Lawes, C.M., Bennett, D.A., Lewington, S., et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2 (2002), 355–368.
195. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
196. Takashima, N., Ohkubo, T., Miura, K., et al. Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. J Hypertens 30 (2012), 2299–2306.
197. Murakami, Y., Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions. J Epidemiol 24 (2014), 96–101.
198. van Dieren, S., Kengne, A.P., Chalmers, J., et al. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract 98 (2012), 83–90.
199. Sundstrom, J., Arima, H., Woodward, M., et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384 (2014), 591–598.
200. Turnbull, F., Neal, B., Algert, C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005), 1410–1419.
201. Wang, J.G., Staessen, J.A., Franklin, S.S., et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 45 (2005), 907–913.
202. Turnbull, F., Woodward, M., Neal, B., et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29 (2008), 2669–2680.
203. Turnbull, F., Neal, B., Ninomiya, T., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336 (2008), 1121–1123.
204. Du, X., Ninomiya, T., de Galan, B., et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 30 (2009), 1128–1135.
205. Czernichow, S., Ninomiya, T., Huxley, R., et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension 55 (2010), 1193–1198.
206. Heerspink, H.J., Ninomiya, T., Perkovic, V., et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31 (2010), 2888–2896.
207. Ninomiya, T., Zoungas, S., Neal, B., et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens 28 (2010), 1141–1149.
208. Collier, D.J., Poulter, N.R., Dahlof, B., et al. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens 29 (2011), 583–591.
209. Ninomiya, T., Perkovic, V., Turnbull, F., et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ, 347, 2013, f5680.
210. Redon, J., Mancia, G., Sleight, P., et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 59 (2012), 74–83.
211. Ogden, L.G., He, J., Lydick, E., et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 35 (2000), 539–543.
212. van der Leeuw, J., Visseren, F.L.J., Woodward, M., et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension 65 (2015), 115–121.
213. Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
214. Ettehad, D., Emdin, C.A., Kiran, A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
215. Sundstrom, J., Arima, H., Woodward, M., et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384 (2014), 591–598.
216. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials. J Hypertens 32 (2014), 2296–2304.
217. Sundstrom, J., Arima, H., Jackson, R., et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 162 (2015), 184–191.
218. Thompson, A.M., Hu, T., Eshelbrenner, C.L., et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305 (2011), 913–922.
219. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2015), 435–443.
220. Wright, J.T. Jr., Williamson, J.D., Whelton, P.K., et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med 373 (2015), 2103–2116.
221. Czernichow, S., Zanchetti, A., Turnbull, F., et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29 (2011), 4–16.
222. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
223. van Dieren, S., Kengne, A.P., Chalmers, J., et al. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract 98 (2012), 83–90.
224. Montgomery, A.A., Fahey, T., Ben-Shlomo, Y., et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 21 (2003), 1753–1759.
225. Kassai, B., Boissel, J.-P., Cucherat, M., et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag 1 (2005), 163–169.
226. Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(suppl 2) (2014), S49–S73.
227. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(suppl 2) (2014), S1–S45.
228. Ambrosius, W.T., Sink, K.M., Foy, C.G., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11 (2014), 532–546.
229. Cushman, W.C., Grimm, R.H. Jr., Cutler, J.A., et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 (2007), 44i–55i.
230. Yusuf, S., Teo, K.K., Pogue, J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med 358 (2008), 1547–1559.
231. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
232. Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
233. Chobanian, A.V., Bakris, G.L., Black, H.R., et al., the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
234. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 34 (2016), 613–622.
235. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2015), 435–443.
236. Verdecchia, P., Angeli, F., Gentile, G., et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension 68 (2016), 642–653.
237. Bangalore, S., Toklu, B., Gianos, E., et al. Optimal systolic blood pressure target after SPRINT insights from a network meta-analysis of randomized trials. Am J Med 30 (2017), 707–719.e8.
238. Bundy, J.D., Li, C., Stuchlik, P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2 (2017), 775–781.
239. Julius, S., Nesbitt, S.D., Egan, B.M., et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006), 1685–1697.
240. Lawes, C.M., Bennett, D.A., Lewington, S., et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2 (2002), 355–368.
241. Lonn, E.M., Bosch, J., Lopez-Jaramillo, P., et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
242. Neaton, J.D., Grimm, R.H. Jr., Prineas, R.J., et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 270 (1993), 713–724.
243. Reboussin, D.M., Allen, N.B., Griswold, M.E., et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 71 (2018), e116–e135.
244. Psaty, B.M., Lumley, T., Furberg, C.D., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003), 2534–2544.
245. Ambrosius, W.T., Sink, K.M., Foy, C.G., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11 (2014), 532–546.
246. Cushman, W.C., Grimm, R.H. Jr., Cutler, J.A., et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 (2007), 44i–55i.
247. Ambrosius, W.T., Sink, K.M., Foy, C.G., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11 (2014), 532–546.
248. Cushman, W.C., Grimm, R.H. Jr., Cutler, J.A., et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 (2007), 44i–55i.
249. Xu, W., Goldberg, S.I., Shubina, M., et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ, 350, 2015, h158.
250. Brennan, T., Spettell, C., Villagra, V., et al. Disease management to promote blood pressure control among African Americans. Popul Health Manag 13 (2010), 65–72.
251. Bosworth, H.B., Olsen, M.K., Grubber, J.M., et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med 151 (2009), 687–695.
252. Bosworth, H.B., Powers, B.J., Olsen, M.K., et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med 171 (2011), 1173–1180.
253. Green, B.B., Cook, A.J., Ralston, J.D., et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 299 (2008), 2857–2867.
254. Heisler, M., Hofer, T.P., Schmittdiel, J.A., et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial. Circulation 125 (2012), 2863–2872.
255. Margolis, K.L., Asche, S.E., Bergdall, A.R., et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA 310 (2013), 46–56.
256. Aronow, W.S., Fleg, J.L., Pepine, C.J., et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation 123 (2011), 2434–2506.
257. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128 (2013), e240–e327.
258. Fihn, S.D., Blankenship, J.C., Alexander, K.P., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 130 (2014), 1749–1767.
259. Gerhard-Herman, M.D., Gornik, H.L., Barrett, C., et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 (2017), e726–e729.
260. Wright, J.T. Jr., Williamson, J.D., Whelton, P.K., et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med 373 (2015), 2103–2116.
261. Bundy, J.D., Li, C., Stuchlik, P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2 (2017), 775–781.
262. Leenen, F.H., Nwachuku, C.E., Black, H.R., et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48 (2006), 374–384.
263. Zanchetti, A., Julius, S., Kjeldsen, S., et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 24 (2006), 2163–2168.
264. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42 (2003), 239–246.
265. Fihn, S.D., Blankenship, J.C., Alexander, K.P., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 130 (2014), 1749–1767.
266. Fox, K.M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003), 782–788.
267. Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
268. Pfeffer, M.A., Braunwald, E., Moye, L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992), 669–677.
269. Yusuf, S., Sleight, P., Pogue, J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000), 145–153.
270. Leon, M.B., Rosing, D.R., Bonow, R.O., et al. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 48 (1981), 131–139.
271. Staessen, J.A., Fagard, R., Thijs, L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 (1997), 757–764.
272. Freemantle, N., Cleland, J., Young, P., et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318 (1999), 1730–1737.
273. de Peuter, O.R., Lussana, F., Peters, R.J.G., et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med 67 (2009), 284–294.
274. Lv, J., Ehteshami, P., Sarnak, M.J., et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
275. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 34 (2016), 613–622.
276. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2015), 435–443.
277. Goldstein, R.E., Boccuzzi, S.J., Cruess, D., et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83 (1991), 52–60.
278. Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation 131 (2015), 34–42.
279. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128 (2013), e240–e327.
280. Aronow, W.S., Ahn, C., Kronzon, I., Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 80 (1997), 207–209.
281. van Veldhuisen, D.J., Cohen-Solal, A., Bohm, M., et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53 (2009), 2150–2158.
282. Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
283. Massie, B.M., Carson, P.E., McMurray, J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
284. Klahr, S., Levey, A.S., Beck, G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330 (1994), 877–884.
285. Ruggenenti, P., Perna, A., Loriga, G., et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365 (2005), 939–946.
286. Wright, J.T. Jr., Bakris, G., Greene, T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002), 2421–2431.
287. Upadhyay, A., Earley, A., Haynes, S.M., et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 154 (2011), 541–548.
288. Lv, J., Ehteshami, P., Sarnak, M.J., et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
289. Jafar, T.H., Stark, P.C., Schmid, C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139 (2003), 244–252.
290. Lambers Heerspink, H.J., Brantsma, A.H., de Zeeuw, D., et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168 (2008), 897–905.
291. Lambers Heerspink, H.J., Gansevoort, R.T., Brenner, B.M., et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 21 (2010), 1355–1360.
292. Contreras, G., Greene, T., Agodoa, L.Y., et al. Blood pressure control, drug therapy, and kidney disease. Hypertension 46 (2005), 44–50.
293. Esnault, V.L., Brown, E.A., Apetrei, E., et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 30 (2008), 482–498.
294. Marin, R., Ruilope, L.M., Aljama, P., et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 19 (2001), 1871–1876.
295. Giatras, I., Lau, J., Levey, A.S., Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 127 (1997), 337–345.
296. Wright, J.T. Jr., Williamson, J.D., Whelton, P.K., et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med 373 (2015), 2103–2116.
297. Cross, N.B., Webster, A.C., Masson, P., et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev, 2009, CD003598.
298. Anderson, C.S., Heeley, E., Huang, Y., et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368 (2013), 2355–2365.
299. Qureshi, A.I., Palesch, Y.Y., Barsan, W.G., et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 375 (2016), 1033–1043.
300. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995), 1581–1587.
301. Hacke, W., Kaste, M., Bluhmki, E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (2008), 1317–1329.
302. Ahmed, N., Wahlgren, N., Brainin, M., et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 40 (2009), 2442–2449.
303. Robinson, T.G., Potter, J.F., Ford, G.A., et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 9 (2010), 767–775.
304. He, J., Zhang, Y., Xu, T., et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA 311 (2014), 479–489.
305. Wang, H., Tang, Y., Rong, X., et al. Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis. PLoS ONE, 9, 2014, e97917.
306. Zhao, R., Liu, F.-D., Wang, S., et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore), 94, 2015, e896.
307. Bath, P.M., Krishnan, K., Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev, 10, 2014, CD000039.
308. Sandset, E.C., Bath, P.M.W., Boysen, G., et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377 (2011), 741–750.
309. Liu, L., Wang, Z., Gong, L., et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 32 (2009), 1032–1040.
310. Lakhan, S.E., Sapko, M.T., Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med, 2, 2009, 30.
311. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001), 1033–1041.
312. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 108 (1995), 710–717.
313. Lee, M., Saver, J.L., Hong, K.-S., et al. Renin-angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. Stroke 43 (2012), 113–119.
314. Wang, W.-T., You, L.-K., Chiang, C.-E., et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore), 95, 2016, e3302.
315. Katsanos, A.H., Filippatou, A., Manios, E., et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension 69 (2017), 171–179.
316. Benavente, O.R., Coffey, C.S., Conwit, R., et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382 (2013), 507–515.
317. Arima, H., Chalmers, J., Woodward, M., et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 24 (2006), 1201–1208.
318. Ostergren, J., Sleight, P., Dagenais, G., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 25 (2004), 17–24.
319. Thompson, A.M., Hu, T., Eshelbrenner, C.L., et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305 (2011), 913–922.
320. Bavry, A.A., Anderson, R.D., Gong, Y., et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 55 (2010), 48–53.
321. Zanchetti, A., Julius, S., Kjeldsen, S., et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 24 (2006), 2163–2168.
322. Emdin, C.A., Rahimi, K., Neal, B., et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
323. Arguedas, J.A., Leiva, V., Wright, J.M., Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev, 10, 2013, CD008277.
324. Cushman, W.C., Evans, G.W., Byington, R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study. N Engl J Med 362 (2010), 1575–1585.
325. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2015), 435–443.
326. Margolis, K.L., O'Connor, P.J., Morgan, T.M., et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37 (2014), 1721–1728.
327. Soliman, E.Z., Byington, R.P., Bigger, J.T., et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension 66 (2015), 1123–1129.
328. Lv, J., Ehteshami, P., Sarnak, M.J., et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
329. Bress, A.P., King, J.B., Kreider, K.E., et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care 40 (2017), 1401–1408.
330. Turnbull, F., Neal, B., Algert, C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005), 1410–1419.
331. Whelton, P.K., Barzilay, J., Cushman, W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005), 1401–1409.
332. Palmer, S.C., Mavridis, D., Navarese, E., et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385 (2015), 2047–2056.
333. Schmieder, R.E., Hilgers, K.F., Schlaich, M.P., et al. Renin-angiotensin system and cardiovascular risk. Lancet 369 (2007), 1208–1219.
334. Lim, S., Eckel, R.H., Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord 15 (2014), 329–341.
335. Owen, J.G., Reisin, E., Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep, 17, 2015, 558.
336. Ruderman, N.B., Shulman, G.I., Metabolic syndrome. Jameson, J.L., (eds.) Endocrinology: Adult & Pediatric, 2015, Elsevier Saunders, Philadelphia, PA, 752–759.
337. Mozumdar, A., Liguori, G., Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006. Diabetes Care 34 (2011), 216–219.
338. Chen, J., Muntner, P., Hamm, L.L., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140 (2004), 167–174.
339. Chen, J., Gu, D., Chen, C.-S., et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 22 (2007), 1100–1106.
340. Barzilay, J.I., Davis, B.R., Whelton, P.K., The glycemic effects of antihypertensive medications. Curr Hypertens Rep, 16, 2014, 410.
341. Kostis, J.B., Wilson, A.C., Freudenberger, R.S., et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 (2005), 29–35.
342. Wright, J.T. Jr., Harris-Haywood, S., Pressel, S., et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 168 (2008), 207–217.
343. Wright, J.T. Jr., Probstfield, J.L., Cushman, W.C., et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 169 (2009), 832–842.
344. Black, H.R., Davis, B., Barzilay, J., et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 31 (2008), 353–360.
345. Laurent, S., Boutouyrie, P., Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension 64 (2014), 709–716.
346. Reisin, E., Owen, J., Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection. J Am Soc Hypertens 9 (2015), 156–159.
347. Healey, J.S., Baranchuk, A., Crystal, E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005), 1832–1839.
348. Zhao, D., Wang, Z.-M., Wang, L.-S., Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res 29 (2015), 475–485.
349. Rieck, Å.E., Cramariuc, D., Boman, K., et al. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events. Hypertension 60 (2012), 90–97.
350. Eleid, M.F., Nishimura, R.A., Sorajja, P., et al. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction. Circulation 128 (2013), 1349–1353.
351. Bull, S., Loudon, M., Francis, J.M., et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging 16 (2015), 834–841.
352. Chockalingam, A., Venkatesan, S., Subramaniam, T., et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J, 147, 2004, E19.
353. Scognamiglio, R., Rahimtoola, S.H., Fasoli, G., et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 331 (1994), 689–694.
354. Evangelista, A., Tornos, P., Sambola, A., et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 353 (2005), 1342–1349.
355. Genoni, M., Paul, M., Jenni, R., et al. Chronic beta-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg 19 (2001), 606–610.
356. Suzuki, T., Isselbacher, E.M., Nienaber, C.A., et al. Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol 109 (2012), 122–127.
357. Leenen, F.H., Nwachuku, C.E., Black, H.R., et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48 (2006), 374–384.
358. Wright, J.T. Jr., Probstfield, J.L., Cushman, W.C., et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 169 (2009), 832–842.
359. Wright, J.T. Jr., Dunn, J.K., Cutler, J.A., et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 293 (2005), 1595–1608.
360. Wright, J.T. Jr., Harris-Haywood, S., Pressel, S., et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 168 (2008), 207–217.
361. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002), 2981–2997.
362. Wright, J.T. Jr., Williamson, J.D., Whelton, P.K., et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med 373 (2015), 2103–2116.
363. Wright, J.T. Jr., Bakris, G., Greene, T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002), 2421–2431.
364. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al. Heart disease and stroke statistics–2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
365. Gueyffier, F., Boutitie, F., Boissel, J.P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 126 (1997), 761–767.
366. Turnbull, F., Woodward, M., Neal, B., et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29 (2008), 2669–2680.
367. Turnbull, F., Woodward, M., Neal, B., et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29 (2008), 2669–2680.
368. Wenger, N.K., Ferdinand, K.C., Bairey Merz, C.N., et al. Women, hypertension, and the Systolic Blood Pressure Intervention Trial. Am J Med 129 (2016), 1030–1036.
369. Fletcher, A., Beevers, D.G., Bulpitt, C., et al. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2 (1988), 219–227.
370. Jansen, J., Bonner, C., McKinn, S., et al. General practitioners’ use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. BMJ OPEN, 4, 2014, e004812.
371. Lewis, C.E., Grandits, A., Flack, J., et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med 156 (1996), 377–385.
372. Kloner, R.A., Sowers, J.R., DiBona, G.F., et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 77 (1996), 713–722.
373. Igho Pemu, P., Ofili, E., Hypertension in women: part I. J Clin Hypertens (Greenwich) 10 (2008), 406–410.
374. James, P.R., Nelson-Piercy, C., Management of hypertension before, during, and after pregnancy. Heart 90 (2004), 1499–1504.
375. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122 (2013), 1122–1131.
376. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. 2011, Royal College of Physicians (UK), London, UK.
377. Pucci, M., Sarween, N., Knox, E., et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Rev Clin Pharmacol 8 (2015), 221–231.
378. Moretti, M.E., Caprara, D., Drehuta, I., et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers. Obstet Gynecol Int, 2012, 2012, 658310.
379. Ferrer, R.L., Sibai, B.M., Mulrow, C.D., et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 96 (2000), 849–860.
380. Williamson, J.D., Supiano, M.A., Applegate, W.B., et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 315 (2016), 2673–2682.
381. Calhoun, D.A., Jones, D., Textor, S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51 (2008), 1403–1419.
382. Farias, S., Peacock, W.F., Gonzalez, M., et al. Impact of initial blood pressure on antihypertensive response in patients with acute hypertension. Am J Emerg Med 32 (2014), 833–836.
383. Peacock, W.F., Chandra, A., Char, D., et al. Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure–A Pilot Study (PRONTO). Am Heart J 167 (2014), 529–536.
384. Applegate, W.B., Pressel, S., Wittes, J., et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 154 (1994), 2154–2160.
385. Forette, F., Seux, M.L., Staessen, J.A., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 (1998), 1347–1351.
386. Forette, F., Seux, M.L., Staessen, J.A., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162 (2002), 2046–2052.
387. Lithell, H., Hansson, L., Skoog, I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003), 875–886.
388. Tzourio, C., Anderson, C., Chapman, N., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163 (2003), 1069–1075.
389. Peters, R., Beckett, N., Forette, F., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology 7 (2008), 683–689.
390. Lindenauer, P.K., Pekow, P., Wang, K., et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 353 (2005), 349–361.
391. Shammash, J.B., Trost, J.C., Gold, J.M., et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 141 (2001), 148–153.
392. Wallace, A.W., Au, S., Cason, B.A., Association of the pattern of use of perioperative β-blockade and postoperative mortality. Anesthesiology 113 (2010), 794–805.
393. Andersson, C., Merie, C., Jorgensen, M., et al. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study. JAMA Intern Med 174 (2014), 336–344.
394. Hoeks, S.E., Scholte Op Reimer, W.J.M., van Urk, H., et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg 33 (2007), 13–19.
395. Barrett, T.W., Mori, M., De Boer, D., Association of ambulatory use of statins and beta-blockers with long-term mortality after vascular surgery. J Hosp Med 2 (2007), 241–252.
396. London, M.J., Hur, K., Schwartz, G.G., et al. Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA 309 (2013), 1704–1713.
397. Turan, A., You, J., Shiba, A., et al. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery. Anesth Analg 114 (2012), 552–560.
398. Rosenman, D.J., McDonald, F.S., Ebbert, J.O., et al. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period. J Hosp Med 3 (2008), 319–325.
399. Roshanov, P.S., Rochwerg, B., Patel, A., et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology 126 (2017), 16–27.
400. Fleisher, L.A., Preoperative evaluation of the patient with hypertension. JAMA 287 (2002), 2043–2046.
401. Howell, S.J., Sear, J.W., Foex, P., Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 92 (2004), 570–583.
402. Hart, G.R., Anderson, R.J., Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med 141 (1981), 1125–1127.
403. Devereaux, P.J., Yang, H., Yusuf, S., et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 371 (2008), 1839–1847.
404. Claxton, A.J., Cramer, J., Pierce, C., A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001), 1296–1310.
405. Iskedjian, M., Einarson, T.R., MacKeigan, L.D., et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24 (2002), 302–316.
406. Schroeder, K., Fahey, T., Ebrahim, S., How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 164 (2004), 722–732.
407. Bangalore, S., Kamalakkannan, G., Parkar, S., et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120 (2007), 713–719.
408. Gupta, A.K., Arshad, S., Poulter, N.R., Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55 (2010), 399–407.
409. Sherrill, B., Halpern, M., Khan, S., et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 13 (2011), 898–909.
410. Yang, W., Chang, J., Kahler, K.H., et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 26 (2010), 2065–2076.
411. Artinian, N.T., Fletcher, G.F., Mozaffarian, D., et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 122 (2010), 406–441.
412. Eckel, R.H., Jakicic, J.M., Ard, J.D., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(suppl 1) (2014), S76–S99.
413. Carter, B.L., Rogers, M., Daly, J., et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med 169 (2009), 1748–1755.
414. Clark, C.E., Smith, L.F., Taylor, R.S., et al. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ, 341, 2010, c3995.
415. Proia, K.K., Thota, A.B., Njie, G.J., et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med 47 (2014), 86–99.
416. Santschi, V., Chiolero, A., Colosimo, A.L., et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc, 3, 2014, e000718.
417. Shaw, R.J., McDuffie, J.R., Hendrix, C.C., et al. Effects of nurse-managed protocols in the outpatient management of adults with chronic conditions: a systematic review and meta-analysis. Ann Intern Med 161 (2014), 113–121.
418. Thomas, K.L., Shah, B.R., Elliot-Bynum, S., et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes 7 (2014), 828–834.
419. Carter, B.L., Coffey, C.S., Ardery, G., et al. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes 8 (2015), 235–243.
420. Rakotz, M.K., Ewigman, B.G., Sarav, M., et al. A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients. Ann Fam Med 12 (2014), 352–358.
421. Borden, W.B., Maddox, T.M., Tang, F., et al. Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol 64 (2014), 2196–2203.
422. Jaffe, M.G., Lee, G.A., Young, J.D., et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA 310 (2013), 699–705.
423. Omboni, S., Gazzola, T., Carabelli, G., et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens 31 (2013), 455–467 discussion 467–8.
424. Verberk, W.J., Kessels, A.G.H., Thien, T., Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis. Blood Press Monit 16 (2011), 149–155.
425. Agarwal, R., Bills, J.E., Hecht, T.J.W., et al. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 57 (2011), 29–38.
426. Liu, S., Dunford, S.D., Leung, Y.W., et al. Reducing blood pressure with Internet-based interventions: a meta-analysis. Can J Cardiol 29 (2013), 613–621.
427. Burke, L.E., Ma, J., Azar, K.M.J., et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation 132 (2015), 1157–1213.
428. Svetkey, L.P., Pollak, K.I., Yancy, W.S. Jr., et al. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. Hypertension 54 (2009), 1226–1233.
429. de Lusignan, S., Gallagher, H., Jones, S., et al. Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int 84 (2013), 609–620.
430. Jaffe, M.G., Lee, G.A., Young, J.D., et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA 310 (2013), 699–705.
431. Walsh, J.M.E., McDonald, K.M., Shojania, K.G., et al. Quality improvement strategies for hypertension management: a systematic review. Med Care 44 (2006), 646–657.
432. Carter, B.L., Rogers, M., Daly, J., et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med 169 (2009), 1748–1755.
433. Glynn, L.G., Murphy, A.W., Smith, S.M., et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev., 2010, CD005182.
434. Proia, K.K., Thota, A.B., Njie, G.J., et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med 47 (2014), 86–99.
435. Anchala, R., Pinto, M.P., Shroufi, A., et al. The role of Decision Support System (DSS) in prevention of cardiovascular disease: a systematic review and meta-analysis. PLoS ONE, 7, 2012, e47064.
436. Thomas, K.L., Shah, B.R., Elliot-Bynum, S., et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes 7 (2014), 828–834.
437. Jaffe, M.G., Lee, G.A., Young, J.D., et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA 310 (2013), 699–705.
438. Agarwal, R., Bills, J.E., Hecht, T.J.W., et al. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 57 (2011), 29–38.
439. Hysong, S.J., Simpson, K., Pietz, K., et al. Financial incentives and physician commitment to guideline-recommended hypertension management. Am J Manag Care 18 (2012), e378–e391.
440. Petersen, L.A., Simpson, K., Pietz, K., et al. Effects of individual physician-level and practice-level financial incentives on hypertension care: a randomized trial. JAMA 310 (2013), 1042–1050.
441. Karunaratne, K., Stevens, P., Irving, J., et al. The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3-5. Nephrol Dial Transplant 28 (2013), 2107–2116.
442. Maimaris, W., Paty, J., Perel, P., et al. The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med, 10, 2013, e1001490.
443. Smith, S.C. Jr., Benjamin, E.J., Bonow, R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124 (2011), 2458–2473.
444. Fihn, S.D., Blankenship, J.C., Alexander, K.P., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 130 (2014), 1749–1767.
445. Fihn, S.D., Gardin, J.M., Abrams, J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126 (2012), e354–e471.
446. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128 (2013), e240–e327.
447. Standards of Medical Care in Diabetes–2016: Summary of Revisions. Diabetes Care 39:suppl 1 (2016), S4–S5.